Survivorship – Breast Cancer: Bone Health

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

PRESENTER

- Post-menopausal women
- Pre-menopausal on tamoxifen or GnRH
- Women on aromatase inhibitors

TREATMENT

- Repeat tests in 2 years and
- Reinforce universal recommendations

A

- Ergocalciferol 50,000 IU once a week for 8 weeks, then continue once a month, or
- Over the counter vitamin D 3 1,000-2,000 IU daily and
- Recheck vitamin D, calcium, and albumin on the next visit and
- Reinforce universal recommendations

- Reinforce universal recommendations and
- Repeat DXA every 1-2 years and
- Consider medical therapy or referral to bone health specialist based on risk factors (assess by FRAX)

- Start bisphosphonates:
  - Alendronate 70 mg po weekly, or
  - Risedronate 35 mg po weekly or 150 mg po monthly, or
  - Ibandronate 150 mg po monthly or 3 mg IV every 3 months, or
  - Zoledronic acid 5 mg IV once a year (use institutional order set) or
- Start denosumab at 60 mg subcutaneously every 6 months (use institutional order set) or
- Refer to bone health specialist and
- Reinforce universal recommendations

- If bone loss risks have changed significantly or major therapeutic intervention has been undertaken, obtain a 12 month follow up DXA

- Start universal recommendations and
- Refer to Bone Health Specialist

GnRH = Gonadotropin-releasing hormone
BMD = Bone Mineral Density
DXA = Dual-energy X-ray Absorptiometry
IU = International Units

1 25-hydroxyvitamin D, also known as 25-hydroxycholecalciferol, calcidiol or abbreviated as 25-OH Vitamin D, the main vitamin D metabolite circulating in plasma

2 Universal recommendations:
- Elemental calcium 1,000 – 1,200 mg/day from all sources
- Avoid tobacco (see Tobacco Cessation algorithm)
- Vitamin D 800 – 1,000 IU/day
- Limit alcohol
- Weight-bearing/muscle - strengthening exercises (see Physical Activity algorithm)
- Limit caffeine

3 Abnormal BMD: Osteopenia, T-score between -1.0 and -2.4; Osteoporosis, T-score ≤ -2.5

4 FRAX®, Fracture Risk Assessment Tool at www.shef.ac.uk/frax

5 If vitamin D level is < 26 ng/mL, replenish with supplementation prior to initiating medical therapy for osteoporosis. See Box A for recommendation on vitamin D repletion.

Copyright 2021 The University of Texas MD Anderson Cancer Center

Department of Clinical Effectiveness V7
Approved by the Executive Committee of the Medical Staff on 02/23/2021
SUGGESTED READINGS


The DIPART (Vitamin D Individual Patient Analysis of Randomized Trials) Group. (2010). Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. BMJ, 340(7738), b5463. doi:10.1136/bmj.b5463

DEVELOPMENT CREDITS

This survivorship algorithm is based on majority expert opinion of the Breast Survivorship work group at the University of Texas MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following:

- Therese Bevers, MD (Cancer Prevention)
- Abenaa Brewster, MD (Cancer Prevention)
- Theresa A. Guise, MD (Endocrine Neoplasia and HD)
- Katherine Gilmore, MPH (Cancer Survivorship)
- Gabriel N. Hortobagyi, MD (Breast Medical Oncology)
- Mimi I-Nan Hu, MD (Endocrine Neoplasia and HD)†
- Thoa Kazantsev, MSN, RN, OCN♦
- Huifang Linda Lu, MD, PhD (Rheumatology)†
- Eric A. Strom, MD (Radiation Oncology)

† Core Development Team Leads
♦ Clinical Effectiveness Development Team

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.